www.auvi-q.com Open in urlscan Pro
2606:4700:3036::6815:21fb  Public Scan

Form analysis
2 forms found in the DOM

<form id="payercontact" novalidate="">
  <fieldset>
    <ul>
      <div class="flex-container">
        <li>
          <label for="firstname">*First name</label>
          <input type="text" name="firstname" id="firstname" required="" minlength="3">
          <span id="firstname-error" class="error" aria-live="polite"></span>
        </li>
        <li>
          <label for="lastname">*Last name</label>
          <input type="text" name="lastname" id="lastname" required="" minlength="3">
          <span id="lastname-error" class="error" aria-live="polite"></span>
        </li>
      </div>
      <div class="flex-container">
        <li>
          <label for="email">*Email address</label>
          <input type="email" name="email" id="email" required="">
          <span id="email-error" class="error" aria-live="polite"></span>
        </li>
        <li>
          <label for="title">Title</label>
          <input type="text" name="title" id="title">
          <span id="title-error" class="error" aria-live="polite"></span>
        </li>
      </div>
      <div class="flex-container">
        <li>
          <label for="organization">Organization</label>
          <input type="text" name="organization" id="organization">
          <span id="organization-error" class="error" aria-live="polite"></span>
        </li>
        <li></li>
      </div>
      <div class="checkbox-wrap">
        <li>
          <div class="gray">
            <input type="checkbox" name="age-consent" id="age-consent" required="">
            <label class="age-consent" for="age-consent"> *Yes, I'm at least 18 years old and I allow kaleo, Inc. and its agents ("Kaléo") to use this information to communicate with me about health and product-related information and services, and
              offers regarding its products, like AUVI-Q. </label>
          </div>
          <span id="age-consent-error" class="error" aria-live="polite"></span>
        </li>
        <li>
          <div class="gray">
            <input type="checkbox" name="privacy-notice-consent" id="privacy-notice-consent" required="">
            <label class="privacy-notice-consent" for="privacy-notice-consent"> *I have read and agree to the Kaléo <a href="https://kaleo.com/privacy/" target="_blank"> Privacy Notice</a>. </label>
          </div>
          <span id="privacy-notice-consent-error" class="error" aria-live="polite"></span>
        </li>
      </div>
      <li>
        <p> By clicking "Submit," you agree to disclose your personal information to Kaléo and to be contacted by Kaléo in the future regarding products, services, market research, and/or other information related to anaphylaxis. For more information
          about Kaléo’s privacy practice, please view the <a href="https://kaleo.com/privacy/" target="_blank"> Privacy Notice</a>. </p>
      </li>
      <li>
        <input class="submit-button" type="submit" value="SUBMIT" data-popup="thankyou">
      </li>
    </ul>
  </fieldset>
</form>

POST #

<form class="acsb-form" data-acsb-search="form" enctype="multipart/form-data" action="#" method="POST"> <input type="text" tabindex="0" name="acsb_search" autocomplete="off" placeholder="Search the online dictionary..."
    aria-label="Search the online dictionary..."> <i class="acsbi-search"></i> </form>

Text Content

Skip to Content
↵ENTER
Skip to Menu
↵ENTER
Skip to Footer
↵ENTER
 * Prescribing Information
 * Patient Information
 * Important Safety Information
 * FOR HEALTHCARE PROFESSIONALS

CALL 1-877-30-AUVIQ
 * Doses
 * Real World Evidence
 * Usability Studies
 * Access, Affordability, & Manufacturing
 * For Healthcare Professionals


AUVI-Q IS THE ONLY EPINEPHRINE AUTO-INJECTOR WITH 3 DOSES

AUVI-q 0.1 mg
For infants and toddlers1 weighing 16.5 lbs to 33 lbs
See more information on the first and only FDA-approved epinephrine
auto-injector for infants and toddlers (weighing 16.5 lbs to 33 lbs)
AUVI-Q 0.15 mg
For children1 weighing 33 lbs to 66 lbs AUVI-Q 0.3 mg
For anyone1 weighing 66 lbs or more
See more information on the first and only FDA-approved epinephrine
auto-injector for infants and toddlers (weighing 16.5 lbs to 33 lbs)


ANAPHYLAXIS HEALTHCARE COSTS AND RESOURCE UTILIZATION ARE GROWING CONCERNS FOR
PAYERS, HCPS, AND PATIENTS

National commercial payer claims data indicate a significant healthcare burden
associated with food-induced anaphylaxis2-4

See the data for medical costs and claims here.


REAL-WORLD EVIDENCE SUPPORTS WHY AUVI-Q SHOULD BE COVERED

Present evidence on the healthcare-economic consequences of patients with
anaphylaxis5


TOTAL COST OF CARE BREAKDOWN IN THE MATCHED POPULATION5

Healthcare resource consumption was based on a 3-month episode of care following
the index data of the anaphylaxis event.5

The objective of the study was to analyze healthcare resource use and costs of
care in non-matched and matched patient populations who experienced anaphylaxis
and were previously prescribed AUVI-Q vs other epinephrine auto-injectors
(EAIs).5
This study was funded by Kaléo.

Download the study here.

Total costs of care during the 3 month post-index period excluding prescription
costs were

$427 less

in the AUVI-Q cohort compared to the other EAI cohort.

Inpatient costs post index were

$162 less

for AUVI-Q patients, which is in line with the fewer hospitalizations observed
among AUVI-Q patients.

For more information about AUVI-Q click here.


THE IMPORTANCE OF DEVICE DESIGN ON SUCCESSFUL EPINEPHRINE ADMINISTRATION


AUVI-Q IS DESIGNED TO BE EASY TO USE AND EASY TO CARRY

VOICE INSTRUCTIONS

POCKET SIZED

AUTO-RETRACTABLE NEEDLE

AUVI-Q voice instructions remind patients to seek emergency medical care after
use.


FOR INFANTS AND TODDLERS WEIGHING 16.5 LBS-33 LBS

AUVI-q 0.1 mg was designed to mitigate the risk of needle injury when
administering epinephrine to infants and toddlers 16.5 lbs-33 lbs.

To learn more about AUVI-q 0.1 mg designed for infants and toddlers click here.

Instruct caregivers to hold the leg of young children and infants firmly in
place and limit movement prior to and during injection to minimize the risk of
injection-related injury.1

Patients should seek emergency medical care immediately after use.


HEAD-TO-HEAD STUDIES: AUVI-Q VS EPIPEN® (EPINEPHRINE INJECTION, USP)6,7

See the full details of these studies here.

Study 1:


AUVI-Q WAS EASIER TO USE THAN EPIPEN FOR UNTRAINED USERS6

In a randomized, cross-over usability study, untrained adults aged 18-65 years
(N = 96) used 0.15 mg AUVI-Q and EpiPen Jr trainers to simulate epinephrine
administration to a child-sized manikin.

The untrained adults had no prior experience with epinephrine auto-injectors and
were not provided with the devices prior to starting the simulation.

Significantly more untrained adults completed key injection tasks with AUVI-Q6


Key injection tasks were defined as the minimum tasks required for a patient to
receive an epinephrine dose.

As this was a simulated use study, participants may not have experienced the
same level of stress that they might experience during anaphylaxis.

Study was conducted by kaleo, Inc.

Study 2:


AUVI-Q WAS PREFERRED OVER EPIPEN FOR BOTH ITS SIZE AND SHAPE7

A study of 693 people aged 11 to 65 years was conducted to determine whether
adults (N = 241), caregivers (N = 228), and children (N = 224) with and without
EAI experience prefer using the AUVI-Q device compared to the EpiPen.

EpiPen® and EpiPen Jr® are registered trademarks of Mylan Inc.


KALÉO IS COMMITTED TO IMPROVING PATIENT ACCESS AND AVAILABILITY TO AUVI-Q

We continue to engage closely with payers and insurance companies to expand
formulary access for AUVI-Q. Effective January 2022, the list price for AUVI-Q
will be $575.00. Most patients do not pay list price. Out-of-pocket costs may
vary based on insurance coverage. Kaléo remains committed to ensuring that
eligible patients with commercial insurance, or those facing financial hardship,
should be able to obtain AUVI-Q affordably through our access program. For
additional questions or information, please contact our market access team at
marketaccess@kaleo.com


THERE IS A STRONG DEMAND BY HEALTHCARE PROVIDERS AND PATIENTS FOR AUVI‑Q

>2.6 million
AUVI-Q PRESCRIPTIONS written since 2017
#1 prescribed
AUVI-Q is the #1 prescribed epinephrine auto-injector by allergists in the US8


AUVI-Q IS MANUFACTURED IN THE US ACCORDING TO THE HIGHEST STANDARDS

AUVI-Q is the Only Approved Epinephrine Auto-injector to:
 * Never experienced a shortage since Kaléo launched the product, despite having
   produced ~8 million auto-injectors to date8*
 * Achieve the FDA’s mandated draft guidance of 99.999% manufacturing
   reliability
 * Have passed all the Department of Defense military standard durability tests

*As of 09/01/2021


WHO CAN I CONTACT IF I HAVE QUESTIONS ABOUT AUVI-Q?

We are available to answer any questions you may have about AUVI-Q.
Please contact us at marketaccess@kaleo.com.
GET THE INFORMATION YOU NEED FOR AUVI-Q
To learn more about AUVI-Q and receive up-to-date information, please fill out
the form below:
* Required
   *First name *Last name
   *Email address Title
   Organization
   *Yes, I'm at least 18 years old and I allow kaleo, Inc. and its agents
   ("Kaléo") to use this information to communicate with me about health and
   product-related information and services, and offers regarding its products,
   like AUVI-Q.
   *I have read and agree to the Kaléo Privacy Notice.

 * By clicking "Submit," you agree to disclose your personal information to
   Kaléo and to be contacted by Kaléo in the future regarding products,
   services, market research, and/or other information related to anaphylaxis.
   For more information about Kaléo’s privacy practice, please view the Privacy
   Notice.

 * 

INDICATION AND IMPORTANT SAFETY INFORMATION

READ MORE

INDICATION

AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat
life-threatening allergic reactions, including anaphylaxis, in people who are at
risk for or have a history of serious allergic reactions.

IMPORTANT SAFETY INFORMATION

AUVI-Q is for immediate self (or caregiver) administration and does not take the
place of emergency medical care. Seek immediate medical treatment after using
AUVI-Q. Each AUVI-Q contains a single dose of epinephrine. AUVI-Q should only be
injected into your outer thigh, through clothing if necessary. If you inject a
young child or infant with AUVI-Q, hold their leg firmly in place before and
during the injection to prevent injuries. Do not inject AUVI-Q into any other
part of your body, such as into veins, buttocks, fingers, toes, hands, or feet.
If this occurs, seek immediate medical treatment and make sure to inform the
healthcare provider of the location of the accidental injection. Only a
healthcare provider should give additional doses of epinephrine if more than two
doses are necessary for a single allergic emergency.

Rarely, patients who use AUVI-Q may develop infections at the injection site
within a few days of an injection. Some of these infections can be serious. Call
your healthcare provider right away if you have any of the following symptoms at
an injection site: redness that does not go away, swelling, tenderness, or the
area feels warm to the touch.

If you have certain medical conditions, or take certain medicines, your
condition may get worse or you may have more or longer lasting side effects when
you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines
you take, especially medicines for asthma. Also tell your healthcare provider
about all of your medical conditions, especially if you have asthma, a history
of depression, thyroid problems, Parkinson’s disease, diabetes, heart problems
or high blood pressure, have any other medical conditions, are pregnant or plan
to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine
should be used with caution if you have heart disease or are taking certain
medicines that can cause heart-related (cardiac) symptoms.

Common side effects include fast, irregular or ‘pounding’ heartbeat, sweating,
shakiness, headache, paleness, feelings of over excitement, nervousness, or
anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These
side effects usually go away quickly, especially if you rest. Tell your
healthcare provider if you have any side effect that bothers you or that does
not go away.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of
allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and
exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of
anaphylactic reactions or who are at increased risk for anaphylaxis.

IMPORTANT SAFETY INFORMATION

AUVI-Q is intended for immediate self-administration as emergency supportive
therapy only and is not a substitute for immediate medical care. In conjunction
with the administration of epinephrine, the patient should seek immediate
medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for
single-use injection. More than two sequential doses of epinephrine should only
be administered under direct medical supervision. Since the doses of epinephrine
delivered from AUVI-Q are fixed, consider using other forms of injectable
epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do
not inject intravenously, or into buttock, digits, hands, or feet. Instruct
caregivers to hold the leg of young children and infants firmly in place and
limit movement prior to and during injection to minimize the risk of
injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported
following epinephrine injection. Advise patients to seek medical care if they
develop any of the following symptoms at an injection site: redness that does
not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart
diseases, and in patients who are on medications that may sensitize the heart to
arrhythmias, because it may precipitate or aggravate angina pectoris and produce
ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation,
have been reported in patients with underlying cardiac disease or taking cardiac
glycosides or diuretics. Patients with certain medical conditions or who take
certain medications for allergies, depression, thyroid disorders, diabetes, and
hypertension, may be at greater risk for adverse reactions. Common adverse
reactions to epinephrine include anxiety, apprehensiveness, restlessness,
tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and
vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 * 
 * 
 * 

 * Contact us at 1-877-30-AUVIQ
 * Privacy Notice
 * References

AUVI-Q® and AUVI-q® are registered trademarks of kaleo, Inc. Other referenced
trademarks are owned by their respective third party owners.
© 2021 kaleo, Inc. CM-US-AQ-2163


INDICATION
AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of
allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and
exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of
anaphylactic reactions or who are at increased risk for anaphylaxis.

IMPORTANT SAFETY INFORMATION
AUVI-Q is intended for immediate self-administration as emergency supportive
therapy only and is not a substitute for immediate medical care. In conjunction
with the administration of epinephrine, the patient should seek immediate
medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for
single-use injection. More than two sequential doses of epinephrine should only
be administered under direct medical supervision. Since the doses of epinephrine
delivered from AUVI-Q are fixed, consider using other forms of injectable
epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do
not inject intravenously, or into buttock, digits, hands, or feet. Instruct
caregivers to hold the leg of young children and infants firmly in place and
limit movement prior to and during injection to minimize the risk of
injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported
following epinephrine injection. Advise patients to seek medical care if they
develop any of the following symptoms at an injection site: redness that does
not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart
diseases, and in patients who are on medications that may sensitize the heart to
arrhythmias, because it may precipitate or aggravate angina pectoris and produce
ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation,
have been reported in patients with underlying cardiac disease or taking cardiac
glycosides or diuretics. Patients with certain medical conditions or who take
certain medications for allergies, depression, thyroid disorders, diabetes, and
hypertension, may be at greater risk for adverse reactions. Common adverse
reactions to epinephrine include anxiety, apprehensiveness, restlessness,
tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and
vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


YOU ARE LEAVING WWW.AUVI-Q.COM

Kaléo is not responsible for the way information is processed by sites linked to
this one. Please review those sites’ privacy policies and terms of use to
understand how your information will be processed. Linking to any other site is
at your own risk.

PROCEED


THANK YOU!

We look forward to staying in touch.


REFERENCES

 * 1. AUVI-Q [Prescribing Information]. Richmond, VA: kaleo, Inc.;
   https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6180fb40-7fca-4602-b3da-ce62b8cd2470&type=display.
 * 2. FARE. FAIR health reports that food allergy prevalence, treatment and
   costs have skyrocketed in past decade. Accessed August 31, 2021.
   https://www.foodallergy.org/media-room/fair-health-reports-food-allergy-prevalence-treatment-and-costs-have-skyrocketed-past.
 * 3. Blue Cross Blue Shield Report. Childhood allergies in America. March 13,
   2018. Accessed August 31, 2021.
   https://www.foodallergy.org/media-room/fair-health-reports-food-allergy-prevalence-treatment-and-costs-have-skyrocketed-past.
 * 4. Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood
   food allergy in the United States. JAMA Pediatr. 2013;167(11):1026-1031.
 * 5. Zah V, M. De Angelo D, Matveev N, McDonnell A. A U.S. commercial claims
   analysis of characteristics and healthcare costs of patients with anaphylaxis
   prescribed AUVI-Q versus other epinephrine auto-injectors. Poster presented
   at AMCP Nexus 2020 Virtual Conference; October 19, 2020. Session T2.
 * 6. Kessler C, Edwards E, Dissinger E, Sye S, Visich T, Grant E. Usability and
   preference of epinephrine auto-injectors: Auvi-Q and EpiPen Jr. Ann Allergy
   Asthma Immunol. 2019:123(3):256-262.
 * 7. Camargo CA Jr., Guana A, Wang S, Simons FER. Auvi-Q versus EpiPen:
   preferences of adults, caregivers, and children. J Allergy Clin Immunol
   Pract. 2013;1(3):266-272.e1-e3
 * 8. Data on file. kaleo, Inc.


THANK YOU!

We look forward to staying in touch.

INDICATION AND IMPORTANT SAFETY INFORMATION

READ MORE

INDICATION

AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat
life-threatening allergic reactions, including anaphylaxis, in people who are at
risk for or have a history of serious allergic reactions.

IMPORTANT SAFETY INFORMATION

AUVI-Q is for immediate self (or caregiver) administration and does not take the
place of emergency medical care. Seek immediate medical treatment after using
AUVI-Q. Each AUVI-Q contains a single dose of epinephrine. AUVI-Q should only be
injected into your outer thigh, through clothing if necessary. If you inject a
young child or infant with AUVI-Q, hold their leg firmly in place before and
during the injection to prevent injuries. Do not inject AUVI-Q into any other
part of your body, such as into veins, buttocks, fingers, toes, hands, or feet.
If this occurs, seek immediate medical treatment and make sure to inform the
healthcare provider of the location of the accidental injection. Only a
healthcare provider should give additional doses of epinephrine if more than two
doses are necessary for a single allergic emergency.

Rarely, patients who use AUVI-Q may develop infections at the injection site
within a few days of an injection. Some of these infections can be serious. Call
your healthcare provider right away if you have any of the following symptoms at
an injection site: redness that does not go away, swelling, tenderness, or the
area feels warm to the touch.

If you have certain medical conditions, or take certain medicines, your
condition may get worse or you may have more or longer lasting side effects when
you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines
you take, especially medicines for asthma. Also tell your healthcare provider
about all of your medical conditions, especially if you have asthma, a history
of depression, thyroid problems, Parkinson’s disease, diabetes, heart problems
or high blood pressure, have any other medical conditions, are pregnant or plan
to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine
should be used with caution if you have heart disease or are taking certain
medicines that can cause heart-related (cardiac) symptoms.

Common side effects include fast, irregular or ‘pounding’ heartbeat, sweating,
shakiness, headache, paleness, feelings of over excitement, nervousness, or
anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These
side effects usually go away quickly, especially if you rest. Tell your
healthcare provider if you have any side effect that bothers you or that does
not go away.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of
allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and
exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of
anaphylactic reactions or who are at increased risk for anaphylaxis.

IMPORTANT SAFETY INFORMATION

AUVI-Q is intended for immediate self-administration as emergency supportive
therapy only and is not a substitute for immediate medical care. In conjunction
with the administration of epinephrine, the patient should seek immediate
medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for
single-use injection. More than two sequential doses of epinephrine should only
be administered under direct medical supervision. Since the doses of epinephrine
delivered from AUVI-Q are fixed, consider using other forms of injectable
epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do
not inject intravenously, or into buttock, digits, hands, or feet. Instruct
caregivers to hold the leg of young children and infants firmly in place and
limit movement prior to and during injection to minimize the risk of
injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported
following epinephrine injection. Advise patients to seek medical care if they
develop any of the following symptoms at an injection site: redness that does
not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart
diseases, and in patients who are on medications that may sensitize the heart to
arrhythmias, because it may precipitate or aggravate angina pectoris and produce
ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation,
have been reported in patients with underlying cardiac disease or taking cardiac
glycosides or diuretics. Patients with certain medical conditions or who take
certain medications for allergies, depression, thyroid disorders, diabetes, and
hypertension, may be at greater risk for adverse reactions. Common adverse
reactions to epinephrine include anxiety, apprehensiveness, restlessness,
tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and
vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


PRIVACY PREFERENCE CENTER

Cookie Statement

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences, or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in, or filling in forms.

You can set your browser to block or alert you about these cookies, but then
some parts of the site will not work. These cookies do not store any personally
identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site.

All information these cookies collect is aggregated and therefore anonymous. If
you do not allow these cookies we will not know when you have visited our site,
and will not be able to monitor its performance.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites.

They do not store directly personal information, but are based on uniquely
identifying your browser and internet device. If you do not allow these cookies,
you will experience less targeted advertising.

Back Button Performance Cookies



Vendor Search Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Save Settings


We use cookies to ensure that you have the best experience on our site. We also
share information about your use of our site with analytics partners. Click
"Cookie Settings" to update your personal cookie preferences or review our
Privacy Notice

Cookies Settings Yes, Use Cookies




English
Accessibility Adjustments
Reset Settings Statement Hide Interface
Choose the right accessibility profile for you
OFF ON
Seizure Safe Profile Eliminates flashes and reduces color
This profile enables epileptic and seizure prone users to browse safely by
eliminating the risk of seizures that result from flashing or blinking
animations and risky color combinations.
OFF ON
Vision Impaired Profile Enhances the website's visuals
This profile adjusts the website, so that it is accessible to the majority of
visual impairments such as Degrading Eyesight, Tunnel Vision, Cataract,
Glaucoma, and others.
OFF ON
Cognitive Disability Profile Assists with reading and focusing
This profile provides various assistive features to help users with cognitive
disabilities such as Autism, Dyslexia, CVA, and others, to focus on the
essential elements of the website more easily.
OFF ON
ADHD Friendly Profile More focus and fewer distractions
This profile significantly reduces distractions, to help people with ADHD and
Neurodevelopmental disorders browse, read, and focus on the essential elements
of the website more easily.
OFF ON
Blind Users (Screen-reader) Use the website with your screen-reader
This profile adjusts the website to be compatible with screen-readers such as
JAWS, NVDA, VoiceOver, and TalkBack. A screen-reader is software that is
installed on the blind user’s computer and smartphone, and websites should
ensure compatibility with it.

Note: This profile prompts automatically to screen-readers.
OFF ON
Keyboard Navigation (Motor) Use the website with the keyboard
This profile enables motor-impaired persons to operate the website using the
keyboard Tab, Shift+Tab, and the Enter keys. Users can also use shortcuts such
as “M” (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics)
to jump to specific elements.

Note: This profile prompts automatically for keyboard users.
Content Adjustments
Content Scaling
Default

Readable Font
Highlight Titles
Highlight Links
Text Magnifier
Adjust Font Sizing
Default

Align Center
Adjust Line Height
Default

Align Left
Adjust Letter Spacing
Default

Align Right
Color Adjustments
Dark Contrast
Light Contrast
Monochrome
High Saturation
Adjust Text Colors
Cancel
High Contrast
Adjust Title Colors
Cancel
Low Saturation
Adjust Background Colors
Cancel
Orientation Adjustments
Mute Sounds
Hide Images
Read Mode
Reading Guide
Useful Links
Select an option Home Header Footer Main Content
Stop Animations
Reading Mask
Highlight Hover
Highlight Focus
Big Black Cursor
Big White Cursor
HIDDEN_ADJUSTMENTS
Keyboard Navigation
Accessible Mode
Screen Reader Adjustments
Read Mode
Web Accessibility Solution By accessiBe
Choose the Interface Language
English
Español
Deutsch
Português
Français
Italiano
עברית
繁體中文
Pусский
عربى
عربى
Nederlands
繁體中文
日本語
Accessibility StatementCompliance status

We firmly believe that the internet should be available and accessible to anyone
and are committed to providing a website that is accessible to the broadest
possible audience, regardless of ability.

To fulfill this, we aim to adhere as strictly as possible to the World Wide Web
Consortium’s (W3C) Web Content Accessibility Guidelines 2.1 (WCAG 2.1) at the AA
level. These guidelines explain how to make web content accessible to people
with a wide array of disabilities. Complying with those guidelines helps us
ensure that the website is accessible to blind people, people with motor
impairments, visual impairment, cognitive disabilities, and more.

This website utilizes various technologies that are meant to make it as
accessible as possible at all times. We utilize an accessibility interface that
allows persons with specific disabilities to adjust the website’s UI (user
interface) and design it to their personal needs.

Additionally, the website utilizes an AI-based application that runs in the
background and optimizes its accessibility level constantly. This application
remediates the website’s HTML, adapts its functionality and behavior for
screen-readers used by blind users, and for keyboard functions used by
individuals with motor impairments.

If you wish to contact the website’s owner please use the website's form

Screen-reader and keyboard navigation

Our website implements the ARIA attributes (Accessible Rich Internet
Applications) technique, alongside various behavioral changes, to ensure blind
users visiting with screen-readers can read, comprehend, and enjoy the website’s
functions. As soon as a user with a screen-reader enters your site, they
immediately receive a prompt to enter the Screen-Reader Profile so they can
browse and operate your site effectively. Here’s how our website covers some of
the most important screen-reader requirements:

 1. Screen-reader optimization: we run a process that learns the website’s
    components from top to bottom, to ensure ongoing compliance even when
    updating the website. In this process, we provide screen-readers with
    meaningful data using the ARIA set of attributes. For example, we provide
    accurate form labels; descriptions for actionable icons (social media icons,
    search icons, cart icons, etc.); validation guidance for form inputs;
    element roles such as buttons, menus, modal dialogues (popups), and others. 
    
    Additionally, the background process scans all of the website’s images. It
    provides an accurate and meaningful image-object-recognition-based
    description as an ALT (alternate text) tag for images that are not
    described. It will also extract texts embedded within the image using an OCR
    (optical character recognition) technology. To turn on screen-reader
    adjustments at any time, users need only to press the Alt+1 keyboard
    combination. Screen-reader users also get automatic announcements to turn
    the Screen-reader mode on as soon as they enter the website.
    
    These adjustments are compatible with popular screen readers such as JAWS,
    NVDA, VoiceOver, and TalkBack.
    
    
 2. Keyboard navigation optimization: The background process also adjusts the
    website’s HTML and adds various behaviors using JavaScript code to make the
    website operable by the keyboard. This includes the ability to navigate the
    website using the Tab and Shift+Tab keys, operate dropdowns with the arrow
    keys, close them with Esc, trigger buttons and links using the Enter key,
    navigate between radio and checkbox elements using the arrow keys, and fill
    them in with the Spacebar or Enter key.
    
    Additionally, keyboard users will find content-skip menus available at any
    time by clicking Alt+2, or as the first element of the site while navigating
    with the keyboard. The background process also handles triggered popups by
    moving the keyboard focus towards them as soon as they appear, not allowing
    the focus to drift outside.
    
    Users can also use shortcuts such as “M” (menus), “H” (headings), “F”
    (forms), “B” (buttons), and “G” (graphics) to jump to specific elements.

Disability profiles supported on our website
 * Epilepsy Safe Profile: this profile enables people with epilepsy to safely
   use the website by eliminating the risk of seizures resulting from flashing
   or blinking animations and risky color combinations.
 * Vision Impaired Profile: this profile adjusts the website so that it is
   accessible to the majority of visual impairments such as Degrading Eyesight,
   Tunnel Vision, Cataract, Glaucoma, and others.
 * Cognitive Disability Profile: this profile provides various assistive
   features to help users with cognitive disabilities such as Autism, Dyslexia,
   CVA, and others, to focus on the essential elements more easily.
 * ADHD Friendly Profile: this profile significantly reduces distractions and
   noise to help people with ADHD, and Neurodevelopmental disorders browse,
   read, and focus on the essential elements more easily.
 * Blind Users Profile (Screen-readers): this profile adjusts the website to be
   compatible with screen-readers such as JAWS, NVDA, VoiceOver, and TalkBack. A
   screen-reader is installed on the blind user’s computer, and this site is
   compatible with it.
 * Keyboard Navigation Profile (Motor-Impaired): this profile enables
   motor-impaired persons to operate the website using the keyboard Tab,
   Shift+Tab, and the Enter keys. Users can also use shortcuts such as “M”
   (menus), “H” (headings), “F” (forms), “B” (buttons), and “G” (graphics) to
   jump to specific elements.

Additional UI, design, and readability adjustments
 1. Font adjustments – users can increase and decrease its size, change its
    family (type), adjust the spacing, alignment, line height, and more.
 2. Color adjustments – users can select various color contrast profiles such as
    light, dark, inverted, and monochrome. Additionally, users can swap color
    schemes of titles, texts, and backgrounds with over seven different coloring
    options.
 3. Animations – epileptic users can stop all running animations with the click
    of a button. Animations controlled by the interface include videos, GIFs,
    and CSS flashing transitions.
 4. Content highlighting – users can choose to emphasize essential elements such
    as links and titles. They can also choose to highlight focused or hovered
    elements only.
 5. Audio muting – users with hearing devices may experience headaches or other
    issues due to automatic audio playing. This option lets users mute the
    entire website instantly.
 6. Cognitive disorders – we utilize a search engine linked to Wikipedia and
    Wiktionary, allowing people with cognitive disorders to decipher meanings of
    phrases, initials, slang, and others.
 7. Additional functions – we allow users to change cursor color and size, use a
    printing mode, enable a virtual keyboard, and many other functions.

Assistive technology and browser compatibility

We aim to support as many browsers and assistive technologies as possible, so
our users can choose the best fitting tools for them, with as few limitations as
possible. Therefore, we have worked very hard to be able to support all major
systems that comprise over 95% of the user market share, including Google
Chrome, Mozilla Firefox, Apple Safari, Opera and Microsoft Edge, JAWS, and NVDA
(screen readers), both for Windows and MAC users.

Notes, comments, and feedback

Despite our very best efforts to allow anybody to adjust the website to their
needs, there may still be pages or sections that are not fully accessible, are
in the process of becoming accessible, or are lacking an adequate technological
solution to make them accessible. Still, we are continually improving our
accessibility, adding, updating, improving its options and features, and
developing and adopting new technologies. All this is meant to reach the optimal
level of accessibility following technological advancements. If you wish to
contact the website’s owner, please use the website's form

Hide Accessibility Interface? Please note: If you choose to hide the
accessibility interface, you won't be able to see it anymore, unless you clear
your browsing history and data. Are you sure that you wish to hide the
interface?
Accept Cancel

Continue



Processing the data, please give it a few seconds...